Comparative Pharmacology
Head-to-head clinical analysis: CEFAZOLIN AND DEXTROSE versus ULTRACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFAZOLIN AND DEXTROSE versus ULTRACEF.
CEFAZOLIN AND DEXTROSE vs ULTRACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal agent inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis. Dextrose provides osmotic diuresis and energy source.
Cefadroxil, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis. It is bactericidal against susceptible organisms.
1-2 g IV/IM every 8 hours; maximum 12 g/day.
250 mg orally every 6 hours or 500 mg orally every 12 hours for uncomplicated urinary tract infections; 1 g orally every 12 hours for complicated urinary tract infections.
None Documented
None Documented
1.8 hours (prolonged to 20-40 hours in severe renal impairment, CrCl <10 mL/min)
0.5–1.2 hours in normal renal function; prolonged to 2–4 hours in severe renal impairment (CrCl <10 mL/min).
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal (<5%)
Approximately 90% of an oral dose is excreted unchanged in urine via glomerular filtration and tubular secretion; less than 1% is excreted in feces via biliary elimination.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic